Evidence map›Paper›PMID 26611895›Full record

ArticleBMC neuroscience2015

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.

Edward Rockenstein, Kiren Ubhi, Michael Mante, Jazmin Florio, Anthony Adame, Stefan Winter, Hemma Brandstaetter, Dieter Meier, Eliezer Masliah

RetractedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Edward RockensteinDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, 92093-0624, USA. erockenstein@ucsd.edu.
Kiren UbhiDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, 92093-0624, USA. krockenstein@cox.net.
Michael ManteDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, 92093-0624, USA. mmante@yahoo.com.
Jazmin FlorioDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, 92093-0624, USA. jflorio@ucsd.edu.
Anthony AdameDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, 92093-0624, USA. asadame@ucsd.edu.
Stefan WinterClinical Research and Pharmacology, EVER Neuro Pharma GmbH, Unterach, Austria. Stefan.Winter@everpharma.com.
Hemma BrandstaetterClinical Research and Pharmacology, EVER Neuro Pharma GmbH, Unterach, Austria. Hemma.Brandstaetter@everpharma.com.
Dieter MeierClinical Research and Pharmacology, EVER Neuro Pharma GmbH, Unterach, Austria. Dieter.Meier@everpharma.com.
Eliezer MasliahDepartment of Neurosciences, University of California, La Jolla, San Diego, CA, 92093-0624, USA. emasliah@ucsd.edu.
University of California San Diego · USEVER Neuro Pharma (Austria) · AT

Funding

B-Synuclein as a Treatment for Lewy Body DiseaseR01AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RISSMAN, ROBERT · 2001 to 2021
$5.2M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
NIA NIH HHS AG18440NIA NIH HHS R01 AG018440NIA NIH HHS R37 AG018440
6 · The paper itself

Abstract

backgroundTauopathies are a group of neurodegenerative disorders with accumulation of three-repeat (3R) or four-repeat (4R) Tau. While 3R tau is found in Pick's disease and Alzheimer's disease (AD), 4R tau is more abundant in corticobasal degeneration, progressive supranuclear palsy, and AD. We have previously shown that Cerebrolysin™ (CBL), a neuropeptide mixture with neurotrophic effects, ameliorates the pathology in amyloid precursor protein transgenic (tg) mouse model of AD and 4R tau, however it is unclear if CBL ameliorates the deficits and neuropathology in the mouse model of Pick's disease over expressing 3R tau.

resultsMice expressing 3R tau (L266V and G272V mutations) under the mThy-1 promoter were treated with CBL in two separate groups, the first was 3 months old (treated for 3 months, IP) and the second was 6 months old (treated for 3 months, IP) at the start of the treatment. We found that although the levels of total 3R tau were unchanged, CBL reduced the levels of hyper-phosphorylated tau in both groups of mice. This was accompanied by reduced neurodegenerative pathology in the neocortex and hippocampus in both groups and by improvements in the behavioral deficits in the nest-building test and water maze in the 3-6 month group.

conclusionTaken together these results support the notion that CBL may be beneficial in other taupathy models by reducing the levels of aberrantly phosphorylated tau.

Indexed as

AgingAmino AcidsAnimalsCerebral CortexDisease Models, AnimalGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHippocampusHumansMice, Inbred C57BLMice, TransgenicMutationNeuroprotective AgentsPhosphorylationPick Disease of the BrainProto-Oncogene Proteins c-aktAmino AcidscerebrolysinGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaMAPT protein, humanNeuroprotective AgentsProto-Oncogene Proteins c-akttau Proteins

Identifiers

PMID26611895
PMCPMC4662012
OpenAlexW2175270506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.